Does Abilify cause hair loss? It is a question raised by some patients taking aripiprazole, the atypical antipsychotic licensed in the UK for schizophrenia and bipolar I disorder. Whilst a small number of post-marketing case reports have noted alopecia in people taking aripiprazole, it does not appear as a recognised adverse effect in the UK Summary of Product Characteristics. The evidence for a direct causal link remains limited, and hair loss in this context is likely multifactorial. This article examines what the current evidence shows, how common the association may be, and what steps to take if you notice hair shedding whilst on Abilify.

Abilify and Hair Loss: What the Evidence Shows

Alopecia does not appear in the UK SmPC for aripiprazole as a commonly reported adverse effect, and there is no definitive causal link established between Abilify and hair loss based on current clinical evidence.

Experiencing these side effects? Our pharmacists can help you navigate them →

Abilify is the brand name for aripiprazole, an atypical antipsychotic medicine licensed in the UK for schizophrenia (in adults and adolescents aged 15 years and over), and for the treatment and prevention of recurrence of manic episodes in bipolar I disorder in adults. In adolescents aged 13 years and over, it is also licensed for the treatment of moderate to severe manic episodes in bipolar I disorder (as per NICE TA292). Its use in other conditions — such as adjunctive treatment for major depressive disorder or for irritability associated with autism spectrum disorder — is not a licensed indication in the UK; any such use would be off-label and should only occur under specialist supervision. Aripiprazole holds a UK marketing authorisation granted by the MHRA; the EMA's European Public Assessment Report (EPAR) for Abilify provides further detail on the EU-level evidence base.

When it comes to hair loss — medically termed alopecia — the evidence linking aripiprazole directly to this side effect is limited and not well established. Alopecia does not appear in the Summary of Product Characteristics (SmPC) for aripiprazole as a commonly reported adverse effect. A small number of case reports and spontaneous post-marketing reports submitted to pharmacovigilance databases have noted alopecia in patients taking the medicine, suggesting a possible but rare association.

There is no definitive, officially confirmed causal link between Abilify and hair loss based on current clinical evidence. The MHRA's Yellow Card reporting scheme has received some spontaneous reports of alopecia associated with aripiprazole, but spontaneous reports alone cannot establish causation. Many factors — including the underlying condition being treated, concurrent medicines, nutritional status, and psychological or physical stress — can independently contribute to hair loss, making it difficult to attribute the symptom to any single medicine with certainty.

How Common Is Hair Loss as a Side Effect?

Hair loss is not listed as a recognised adverse effect in the UK SmPC for aripiprazole; where reported through post-marketing surveillance, its frequency is classified as 'not known' and cannot be estimated from available data.

Not sure if this is normal? Chat with one of our pharmacists →

Based on available data, alopecia is not listed as a recognised adverse effect in the UK SmPC for aripiprazole. Where a side effect is identified only through spontaneous post-marketing reports — rather than from controlled clinical trial data — the SmPC convention is to classify its frequency as 'not known' (cannot be estimated from the available data). Describing aripiprazole-associated alopecia as 'uncommon' or 'rare' would therefore be speculative and is not supported by the current UK SmPC.

For reference, the standard EU/UK frequency terminology used in SmPCs is:

• Very common: affecting more than 1 in 10 people

• Common: affecting 1 in 10 to 1 in 100 people

• Uncommon: affecting 1 in 100 to 1 in 1,000 people

• Rare: affecting 1 in 1,000 to 1 in 10,000 people

• Not known: frequency cannot be estimated from available data

By contrast, more frequently reported side effects of aripiprazole — as listed in the UK SmPC — include akathisia (restlessness), nausea, insomnia, and headache. Weight changes have also been reported; the frequency and extent of weight gain can differ between adults and adolescents, and patients should discuss this with their clinician.

It is also worth considering that psychiatric conditions themselves — particularly depression, anxiety, and schizophrenia — are associated with physiological stress responses that can trigger a form of hair shedding known as telogen effluvium (discussed further below). Patients who notice hair loss whilst taking aripiprazole may therefore be experiencing a symptom related to their underlying condition or to the stress of illness, rather than a direct drug effect. The timing of hair loss coinciding with treatment initiation does not necessarily indicate causation, and professional evaluation is always advisable before drawing conclusions.

Why Some Medicines Can Affect Hair Growth

Drug-induced alopecia typically occurs via anagen effluvium or telogen effluvium; antipsychotics as a class are less commonly implicated than mood stabilisers such as sodium valproate, and no clear biological mechanism links aripiprazole to hair loss.

To understand why certain medicines may influence hair growth, it helps to consider the normal hair growth cycle. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Disruption to this cycle — whether through hormonal changes, nutritional deficiencies, systemic illness, or pharmacological agents — can result in increased shedding or reduced regrowth.

Drug-induced alopecia typically occurs through one of two mechanisms. The first is anagen effluvium, where a drug directly disrupts actively dividing hair follicle cells, causing rapid and often diffuse hair loss — this is most commonly associated with chemotherapy agents. The second is telogen effluvium, a more gradual process in which a physiological or pharmacological stressor shifts a large proportion of follicles prematurely into the resting phase, resulting in noticeable shedding approximately two to four months later. NICE Clinical Knowledge Summaries (CKS) on alopecia provide useful UK primary care guidance on distinguishing these patterns and on appropriate investigation.

Several classes of psychiatric medicine have been associated with hair loss to varying degrees, though it should be noted that much of this evidence comes from case reports and observational data rather than controlled trials. Mood stabilisers such as sodium valproate are among the most well-documented causes of drug-induced alopecia in psychiatry. Lithium and some antidepressants have also been implicated in case reports. Antipsychotics as a class are less commonly associated with hair loss, though individual agents — including, rarely, aripiprazole — have appeared in post-marketing reports.

Aripiprazole's mechanism of action involves partial agonism at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, along with antagonism at 5-HT2A receptors. Whether any of these receptor interactions could theoretically influence hair follicle biology is not well understood, and no clear biological mechanism has been established to explain a link between aripiprazole and alopecia.

What to Do If You Notice Hair Loss on Aripiprazole

Do not stop aripiprazole abruptly; speak with your GP or psychiatrist, who will assess the timeline, pattern, and blood tests including thyroid function and ferritin, and consider other contributing causes before attributing hair loss to the medicine.

If you are taking aripiprazole and notice increased hair shedding or thinning, it is important not to stop your medication abruptly. Discontinuing an antipsychotic without medical supervision can lead to a return of symptoms and, in some cases, withdrawal effects. The appropriate first step is to speak with your GP or prescribing psychiatrist so that the hair loss can be properly assessed.

Your clinician will likely consider the following during their evaluation, in line with UK primary care guidance (NICE CKS: Alopecia):

• Timeline: When did the hair loss begin relative to starting or changing medication?

• Pattern: Is the loss diffuse (all over the scalp) or localised? Diffuse loss is more typical of telogen effluvium or drug-related causes.

• Blood tests: Investigations commonly include thyroid function tests (TSH), full blood count, and serum ferritin (iron stores). Vitamin B12, folate, and vitamin D may also be checked if clinically indicated.

• Medication review: Your doctor will review all current medicines, including over-the-counter products and supplements, to identify any other potential contributors.

• Red-flag features: Seek prompt review if you notice scarring, inflammation or pain on the scalp, patchy loss that may suggest alopecia areata, rapid or extensive shedding accompanied by systemic symptoms (such as fatigue, weight change, or fever), or if you are pregnant or have recently given birth.

• Dermatology referral: If the cause remains unclear or the hair loss is significant, referral to a dermatologist may be appropriate.

If investigations reveal a nutritional deficiency, supplementation may help. If aripiprazole is strongly suspected as the cause and the hair loss is distressing, your psychiatrist may consider adjusting the dose or switching to an alternative agent — though this decision must always be weighed carefully against the risk of psychiatric relapse.

You can report suspected side effects directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the evidence base for medicine safety in the UK.

Weighing the Benefits and Side Effects of Abilify

Aripiprazole has a strong evidence base for managing schizophrenia and bipolar disorder, and a possible unconfirmed side effect such as hair loss should not prompt discontinuation without professional guidance, given the significant risks of untreated serious mental illness.

Aripiprazole has a substantial evidence base supporting its efficacy in managing serious mental health conditions within its licensed indications. For many patients, it offers meaningful improvements in symptom control, quality of life, and functional ability. NICE guidelines on psychosis and schizophrenia in adults (e.g., NICE CG178 and its successor guidance) and on bipolar disorder (e.g., NICE CG185 and its successor guidance) recommend that antipsychotic choice should be made through shared decision-making, taking into account the individual patient's clinical needs, preferences, and the side-effect profile of each medicine. NICE does not endorse a single antipsychotic as universally preferred.

In terms of metabolic effects, the BNF and comparative clinical data indicate that aripiprazole is generally associated with a lower propensity for weight gain and metabolic disturbance than some other antipsychotics such as olanzapine or clozapine, though individual responses vary and monitoring remains important for all patients on antipsychotic treatment.

When considering any potential side effect — including the rare and unconfirmed possibility of hair loss — it is essential to weigh this against the established benefits of treatment. Untreated or poorly managed schizophrenia, bipolar disorder, or severe depression carries significant risks, including hospitalisation, self-harm, and reduced life expectancy. A possible, unconfirmed side effect such as hair loss should not, in most cases, be a reason to discontinue an otherwise effective treatment without professional guidance.

Open communication between patient and clinician is central to good prescribing practice. If you have concerns about any side effect — whether confirmed or suspected — raise them at your next appointment. Shared decision-making, as advocated by NICE (NICE NG197), ensures that treatment choices reflect both clinical evidence and individual patient preferences and priorities.

In summary, whilst a small number of reports suggest aripiprazole may rarely be associated with hair loss, the frequency is classified as 'not known' and the evidence does not establish a definitive causal link. Hair loss in this context is likely to be multifactorial. With appropriate investigation and support, most patients can continue their treatment safely and effectively.

Frequently Asked Questions